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1. Introduction
  Chronic obstructive pulmonary disease (COPD) is a 
common respiratory disease with an increasing incidence 
rate year by year. This disease is mainly manifested as 
persistent airway obstruction showing progressive and 
irreversible development. With the gradual decline in lung 
function, the frequency of acute exacerbation increases in 
some patients with severe lung tissue damage, resulting in 
decreased activity tolerance, which not only increases the 
financial burden of the patients, but also seriously affects 
the quality of life of the patients. Currently it is concluded 
that the pathogenesis of acute exacerbation of chronic 
obstructive pulmonary disease (AECOPD) is mainly related 
to pulmonary inflammatory reaction and many other factors, 
including cytokines and inflammatory factors such as IL-
32, MMP-9, PCT, CRP, etc[1-3]. Therefore, decreased levels 
of these factors in the treatment may reduce the frequency 
of AECOPD. In addition, the difference in serum IL-32, 
MMP-9, PCT and CRP levels of patients with AECOPD 
and those with acute asthma attack, and the relationship 
between these levels and the severity of pulmonary function 
impairment are unknown, which need further study.
2. Materials and methods
2.1. General data  
  Fifty patients (Aged between 59-80 years old) with 
AECOPD admitted from October 2013 to August 2014 were 
selected, including 27 males and 23 females. The diagnosis 
and severity assessment were based on the Guideline for 
Diagnosis and Treatment in COPD[4]. In acute asthma attack 
group, there were 45 patients (20 males and 25 females). 
The diagnostic criteria for patients in acute asthma attack 
group were based on Guidelines for diagnosis and treatment 
of bronchial asthma (2013)[5]. The patients in the two 
groups above had not received anti-leukotriene receptor 
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antagonists, corticosteroids and antibiotics within 4 weeks 
before admission. The patients with the following diseases 
were excluded: chronic lung diseases such as tuberculosis, 
bronchiectasis, etc., rheumatic autoimmune disease, 
inflammatory response syndrome and other complications, 
and fungal infections. All patients had no pulmonary 
infection confirmed by chest X-ray or CT. At the same time, 
45 healthy volunteers (Aged between 53-74 years old) were 
selected and enrolled in the control group, including 19 
males and 26 females, who had no history of COPD, asthma 
or allergies, and the pulmonary function was normal. There 
was no history of respiratory infection and no any medicines 
within past 4 weeks were taken.  There were no differences 
in age, sex and occupation structure among three groups.
2.2. Methods
  Before treatment, 5 mL of blood was collected from the 
cubital vein of patients with AECOPD and acute asthma 
attack admitted and healthy volunteers into a dry tube 
without anticoagulant. The blood was placed at room 
temperature for natural coagulation for 20 minutes, and then 
centrifuged for 20 minutes (3 000 rpm). The blood sample 
was centrifuged again if precipitate appeared during the 
preservation process. Then the serum was extracted and 
cryopreserved at -70 曟 for later tests. The instruments 
used were (1) ELIASA: Perlong Medical (Beijing), model: 
DNM-9602; (2) Plate washer: Finland (Thermo Labsystems), 
model: AC8; (3) Centrifuge: high-speed micro-centrifuges 
(domestic), model: TG16W; (4) Incubator: water-jacket 
incubator (domestic), model: GNP-9080. Serum IL-32 and 
MMP-9 was determined by double antibody sandwich ELISA 
assay, PCT was quantified by immunofluorescent double 
antibody sandwich assay, and CRP was determined by 
immunoturbidimetry. The detection range of was 5 ng/L-100 
ng/L for IL-32 and 0.4 毺g/L-20 毺g/L for MMP. The normal 
range was < 0.5 ng/L for PCT and < 10 mg/L for CRP. The kits 
for IL-32 and MMP-9 were provided by Beijing Baiaolaibo 
Science and Technology Co., Ltd. PCT kit was provided 
by Guangzhou Wondfo Biotech Co., Ltd, and CRP kit was 
provided by Beijing Strong Biotechnologies, Inc. All tests 
were conducted strictly in accordance with instructions. 
Pulmonary function test was conducted using German Jaeger 
MS-PFT breathing machine after inhaling bronchodilator 
(ventolin 5 mg). The severity of pulmonary function 
impairment was indicated by FEV1/FVC5 and FEV1%.
2.3. Statistical methods  
  The continuous variables were normally distributed which 
were expressed as mean依standard deviation. ANOVA was 
used for comparison among groups and LSD test was used 
for comparison between two groups. Enumeration data was 
analyzed using Chi-square test. The correlation between 
the grading of pulmonary function, smoking index and 
serum levels of MMP-9 and IL-32, CRP and PCT in AECOPD 
group was analyzed using Spearman rank test. The best 
choice point for determining the sensitivity of AECOPD 
was area under ROC curve. AUC of 0.5-0.7 indicated lower 
accuracy, 0.7-0.9 indicated moderate accuracy and > 0.9 
indicated higher accuracy. All data were processed using 
statistical software SPSS 21.0 and analyzed by two-sided 
test. Significant level was defined as 毩=0.05 and P<0.05 
was considered statistically significant.
3. Results
  The levels of IL-32, MMP-9, PCT and CRP in AECOPD 
group were significantly higher than those of asthma group 
and control group (P<0.05). however, no difference in the 
levels of PCT and CRP was observed between asthma group 
and control group (P>0.05) (Table 1). The levels of MMP-9 
and IL-32 were negatively correlated with pulmonary 
function and positively correlated with smoking index with 
correlation coefficients of 0.493, 0.663, 0.181 and 0.221, 
respectively, suggesting that the worse pulmonary function 
was, the higher smoking index was, the higher the levels 
of MMP-9 and IL-32 were. The levels of PCT and CRP had 
no correlation with pulmonary function but had positive 
correlation with smoking index. Further analysis revealed 
that the levels of IL-32 and MMP-9 increase with the grade 
of pulmonary function increasing, which were the highest 
in patients with grade 4 pulmonary function, significantly 
higher than that in patients with grade 1-3 pulmonary 
function (P<0.05). The level of IL-32 in patients grade 3 
pulmonary function was higher than that in grade 1 and 
2 (P<0.05); however, the level of MMP-9 in patients with 
grade 3 pulmonary function was higher than that in grade 1 
(P<0.05), but had no differences with that in grade 2 (P>0.05) 
(Table 2). PCT, CRP, MMP-9 and IL-32 have diagnostic value 
for AECOPD. MMP-9 was more sensitive in AECOPD patients, 
followed by CRP, then IL-32, and finally PCT (Table 3).
Table 1
Comparason in IL-32 , MMP-9, PCT and CRP among AECOPD group, athma group and control group.
Group PCT(毺g/L) CRP (mg/L) MMP-9 IL-32
AECOPD(n=50)     0.81依0.35*#     28.11依17.14*#  15.93依2.19*#   90.63依18.73*#
Athma(n=45) 0.36依0.2 10.69依7.82 13.04依2.17*  75.17依10.56*
control(n=45)   0.28依0.15   6.15依3.14 9.07依2.02 60.76依10.87
F 61.527 50.537 123.232 53.163
Compared with Asthma group, *P<0.05; Compared with Control group, #P<0.05. 
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Table 2
Relationship between PF and MMP-9, IL-32.
Pulmonary function n MMP-9 IL-32
1 11 14.26依1.59   78.08依6.62
2 15   15.8依1.76*   82.02依10.35
3 14 15.96依1.94*   95.35依12.46*#
4 10 17.83依2.19*#& 109.44依25.41*#&
Compared with pulmonary function grade 1, *P<0.05; Compared with 
pulmonary function grade 2, #P<0.05; Compared with pulmonary 
function grade 3, &P<0.05.
4. Discussion
  Currently it is believed that AECOPD is a kind of chronic 
inflammatory reactions in airways, pulmonary parenchyma 
and vessels are caused and mediated by a variety of 
cytokines and inflammatory factors are produced by various 
cells, such as macrophages, neutrophils and T lymphocytes, 
etc. Cytokines and inflammatory factors are involved in the 
progressive development of airflow limitation and structural 
damage of airway wall and lung parenchyma[6]. IL-32 is 
an important cytokine, which is expressed in a number 
of immune tissues, such as spleen, thymus, leukocytes, 
small intestine, etc. IL-32, which could be produced by 
endogenous secretion by T cells, monocytes and NK cells 
and gene recombination, plays an important role in the 
regulation of inflammation, and it can induce the immune 
cells to produce a variety of other cytokines. In addition, 
the expression of IL-32 in the airway wall is related to 
the infiltration of neutrophils and CD8+ cells and the 
obstruction of airway, suggesting IL-32 may be involved in 
specific immune response of COPD[7]. MMP-9, a calcium 
and zinc-dependent endopeptidase which is mainly 
synthesized and secreted by neutrophils and macrophages 
with main function in maintaining normal metabolism of 
extracellular matrix, it is involved in airway inflammation 
reaction and airway remodeling process. Moreover, the 
excessive secretion of MMP-9 may lead to the destruction of 
pulmonary tissue structure and the expansion of air chamber 
and result in airflow obstruction[8]. PCT, a glycoprotein, is 
the precursor molecule of human calcitonin. Under normal 
condition, PCT is produced by thyroid C cells with low 
serum level (<0.05 ng/mL). In case of bacterial infections 
and septicopyemia, most of PCT is produced by the tissues 
beside the thyroid. The level of PCT is generally not elevated 
in autoimmunity, fungal and viral infections and allergies, 
but is significantly elevated in bacterial infections. PCT is 
not influenced by hormones and immunosuppressive agents, 
and therefore, it has high accuracy and specificity[9]. It can 
be be used to evaluate the severity of disease effectively 
and to judge prognosis of patients with AECOPD. It is 
consider as bacterial infection if PCT＞0.25 毺g/L; when 
the level is 0.26-0.5 毺g/L, relevant anti-infective therapy 
is recommended. Strongly recomand anti-infective therapy 
is strongly recommended with antibiotics if PCT>0.5 毺g/
L. CRP is a non-specific acute phase protein synthesized 
by the liver, which is mainly mediated by IL-6. Under 
physiological state, CRP in 99% of the population is less 
than 10 mL which is not easy to detect. However, in case 
of bacterial infections and other inflammatory stimulation 
may cause elevated synthesis of CRP in the liver leading to 
persistent elevated level of CRP. However, the level of CRP 
rapidly declines after the infection is controlled, and usually 
returns to normal in 1 week. Therefore, serum level of CRP 
can be used as a sensitive indicator for bacterial infections 
in AECOPD, which is significant to the diagnosis and 
treatment of AECOPD[10,11].
  This study showed that serum levels of IL-32, MMP-9 
in the patients with AECOPD and the patients with acute 
asthma attack were higher than those of healthy people, 
suggesting that both these two types of patients had different 
degrees of airway structural damage. In addition, serum 
levels of IL-32 and MMP-9 in AECOPD patients were higher 
than those in patients with acute asthma attack, suggesting 
the degree of airway damage of the former’s structure may 
be more serious than the latter. The reasons may lie in one 
important cause in the pathogenesis of COPD: the imbalance 
of protease/anti-protease. Moreover, MMP-9 can degrade 
extracellular matrix, resulting in airway wall damage, 
expansion of alveolar cavity and finally leading to airway 
remodeling. Another important cause in the pathogenesis of 
COPD is activation of the immune inflammatory reactions, 
and IL-32- involved specific immune response may 
cause the apoptosis of epithelial cells of airways and lung 
tissue, causing airway structure damage and lung tissue 
remodeling[12]. In addition, serum levels of IL-32 and MMP-9 
in patients with AECOPD was negatively correlated with 
FEV1%, further suggesting that the higher concentrations 
of IL-32 and MMP-9 cause greater damage to the airways 
and lung tissue and more severe airflow limitation[13]. 
Table 3
Relationship between IL-32, MMP-9, PCT, CRP and sensitivity in diagnosing AECOPD. 
AUC SD P
95%CI
Critical value Sensitivity Specificity
Lower Bound Upper Bound
PCT (毺g/L) 0.924 0.023 <0.001 0.879 0.970   0.475 84.44% 100.00%
CRP (mgL) 0.965 0.016 <0.001 0.933 0.996 10.500 88.89% 100.00%
MMP9 0.989 0.007 <0.001 0.000 1.000 12.580 96.67%   95.00%
IL-32 0.943 0.021 <0.001 0.902 0.983 73.965 87.78%   87.50%
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However, the level of MMP-9 was not significantly changed 
in patients with grade 1 and 2 pulmonary function, possibly 
due to lesser damage of airways and lung tissue in these 
patients. MMP-9 is more sensitive than the other three 
Index as to AECOPD patients,further represent that the 
relationship between MMP-9 and airway wall damage,airway 
remodeling is closer, can be used as an important index 
to diagnose AECOPD. As markers of inflammation, PCT 
and CRP were elevated more significantly in patients with 
AECOPD, because the infection was the primary cause of 
AECOPD, while acute attack of asthma may be related to 
inhaled allergens. Therefore, PCT and CRP as indicators for 
infection can not only be used to determine the degree of 
infection in patients with AECOPD, but also guide the use 
of antibiotics[14]. The patients with higher smoking index 
had higher concentrations of IL-32, MMP-9, PCT and CRP, 
because compared with healthy smokers, the patients with 
COPD have large amounts of MMP-9 with increased activity 
released by alveolar macrophages, and the expression of 
IL-32 is related to neutrophil infiltration in the airway 
wall. Therefore, the patients with higher smoking index 
had higher concentrations of IL-32 and MMP-9 in airways 
and lung tissue, leading to more severe structural damage 
to the airways and lung tissue and more significant airflow 
limitation[15]. Moreover, smoking worsens the damage to 
airways and lung tissue, which aggravate the infection in the 
patients, leading to elevated levels of PCT and CRP.
  In summary, the levels of serum IL-32, MMP-9, PCT and 
CRP in patients with AECOPD are higher than those in 
patients with acute asthma, suggesting that the increase 
of the levels of IL-32 and MMP-9 has certain relationship 
with AECOPD and can be used as a marker for acute 
exacerbation of COPD to a certain extent. The infection is the 
leading cause of AECOPD; therefore, PCT and CRP can be 
used as an indicator to determine the severity of AECOPD. 
Meanwhile, the increase of levels of IL-32 and MMP-9 were 
negatively correlated with pulmonary function. This study 
is aimed to provide a theoretical basis for the use of matrix 
metalloproteinase regulators and IL32 inhibitors to treat 
and delay the decline in pulmonary function in patients 
with AECOPD. In addition, the levels of IL-32 and MMP-9 
levels were positively correlated with smoking index, further 
suggesting that long-term heavy smoking may cause more 
serious structural damage to lung tissue; therefore, early 
active quitting is important to improve the quality of life and 
reduce the financial burden of patients with COPD. However, 
further study is needed to investigate the role of the above 4 
indicators in the long-term control of patients with COPD.
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